Mechanisms of antinociceptive effects of ouabain in combination with neostigmine in the rat***★
|
Publisher:Quzwzb Publish Time:Thursday, November 20, 2008 Source:Neural Regen Res,2008,3(7),710-3 |
Handong Ouyang, Qiang Li, Weian Zeng, Weixiong He, Peizong Wang
State Key Laboratory of Oncology in Southern China (i.e. Department of Anesthesia, Cancer Center, Sun Yat-sen University), Guangzhou 510060, Guangdong Province, China
Handong Ouyang★, Master, State Key Laboratory of Oncology in Southern China (i.e. Department of Anesthesia, Cancer Center, Sun Yat-sen University), Guangzhou 510060, Guangdong Province, China
Supported by: the National Natural Science Foundation of China, No. 30571794*, C03030301*; and Sci-tech Development Program, No.303040077001*
Ouyang HD, Li Q, Zeng WA, He WX, Wang PZ. Mechanisms of antinociceptive effects of ouabain in combination with neostigmine in the rat. Neural Regen Res 2008;3(7):710-3
| Abstract
BACKGROUND: It has been previously shown that intrathecal administration of either ouabain or neostigmine can produce antinociceptive effects. Moreover, ouabain and neostigmine are differently associated with acetylcholine.
OBJECTIVE: It has been hypothesized that intrathecal administration of ouabain, in combination with neostigmine, can produce antinociceptive synergistic effects. Atropine, as a competitive antagonist, was pre-injected to verify the mechanisms of action.
DESIGN, TIME AND SETTING: This study was a randomized, controlled, animal experiment, performed at the State Key Laboratory of Oncology in Southern China between May 2006 and February 2007.
MATERIALS: A total of 102 healthy, adult, Sprague Dawley rats were included. Ouabain and neostigmine (Sigma, USA), as well as atropine (Tanabe Seiyaku, Japan), were also used.
METHODS: Varied doses of ouabain, neostigmine, and a combination of the two were intrathecally injected into rats. Six rats were allotted for each dose group. Intrathecal pretreatment with atropine was tested 10 minutes prior to intrathecal administration of neostigmine or the combination of ouabain and neostigmine.
MAIN OUTCOME MEASURES: Tail-flick tests were performed to measure tail-flick latency (seconds) prior to and after administration. The response in the tail-flick test was expressed as the percentage of maximum possible effect (% MPE), where % MPE = [tail-flick latency after administration (seconds) -mean baseline value for tail-flick latency]/[10 seconds - the mean baseline value for tail-flick latency (seconds)] × 100%.
RESULTS: Rat spinal intrathecal administration of either ouabain or neostigmine alone produced antinociceptive effects in a dose-dependent manner. Intrathecally administration of neostigmine (0.05, 0.1, 0.3 μg ) in combination with ouabain (1 μg ) produced enhanced antinociceptive effects, with a % MPE of 29%, 78%, and 95%, respectively (P < 0.05). Intrathecally administration of 0.3 μg neostigmine (% MPE: 45%), in combination with 1 μg ouabain (% MPE: 27%) produced potent antinociceptive effects (% MPE: 95%). Intrathecally pre-injected atropine antagonized the antinociceptive effects of neostigmine (3 μg), or a combination of ouabain (1 μg) and neostigmine (0.3 μg) (P < 0.01).
CONCLUSION: Rat spinal intrathecal administration of either ouabain or neostigmine alone produced dose-dependent antinociceptive effects. Ouabain enhanced the antinociceptive effects of neostigmine. Atropine antagonized the antinociceptive effects of neostigmine or the combination of ouabain and neostigmine. This occurs possibly due to the fact that atropine is a competitive antagonist of the muscarinic acetylcholine receptors.
Key Words: ouabain; neostigmine; intrathecal administration; antinociceptive effect
Full text:click
|